Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11266819 | 0.88 | SIGMAR1 (0.44) | ALDH1A1LMNACYP3A4OPRK1OPRM1 | |
| SCHEMBL29646238 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNACYP3A4OPRK1OPRM1 | |
| SCHEMBL218608 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNACYP3A4OPRK1OPRM1 | |
| SCHEMBL29646235 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNACYP3A4OPRK1OPRM1 | |
| SCHEMBL7408641 | 0.76 | KDM4E (0.58) | ALDH1A1LMNACYP3A4PBRM1 | |
| SCHEMBL4236973 | 0.75 | ALDH1A1 (0.49) | ALDH1A1LMNACYP3A4OPRK1OPRM1 | |
| Bromide SCHEMBL8768815 | 0.72 | ESR1 (0.45) | ALDH1A1LMNACYP3A4OPRK1OPRM1 | |
| SCHEMBL6267106 | 0.71 | KDM1A (0.53) | ALDH1A1CYP3A4 | |
| SCHEMBL29784907 | 0.71 | KDM1A (0.53) | ALDH1A1CYP3A4 | |
| SCHEMBL11100764 | 0.71 | KDM4E (0.42) | ALDH1A1LMNACYP3A4OPRK1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | claimed |
| US-20160177354-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | SAFC, INC. | 2016-06-23 | — | — | US | claimed |
| EP-2462115-B1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | claimed |
| US-8703448-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | claimed |
| CN-102574791-A | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS INC | 2012-07-11 | — | — | CN | claimed |
| EP-2462115-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | Infinity Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | claimed |
| WO-2011017551-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | claimed |
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160177354-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | SAFC, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-2462115-B1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | ROYALTY SECURITY, LLC | 2014-12-18 | — | — | US | disclosed |
| US-8703448-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| CN-102574791-A | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS INC | 2012-07-11 | — | — | CN | disclosed |
| EP-2462115-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | Infinity Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2011017551-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | ALDH1A1 693/4885LMNA 3784/4885CYP3A4 62/4885 |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | ALDH1A1 693/4885LMNA 3784/4885CYP3A4 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.